Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Merck & Co., Inc. became the latest healthcare company to strike a major settlement with the Justice Department on Nov. 22, agreeing to pay $950 million to resolve criminal and civil charges stemming from its marketing of the painkiller Vioxx.
As part of the settlement, Merck, Sharp & Dohme, the company's U.S. unit, will plead guilty in Boston federal district court to a single misdemeanor count of violating the Food, Drug, and Cosmetic Act and will pay a $321.6 million criminal fine. Merck will also pay nearly $628.3 million to settle civil allegations that it marketed Vioxx for off-label uses and made false statements about the drug's safety. (The criminal information is here, and the settlement agreement is here.)
Theodore Wells Jr. of Paul, Weiss, Rifkind, Wharton & Garrison and Jack Cinquegrana of Choate Hall & Stewart represented Merck. Wells did not respond to a request for comment, and Cinquegrana referred a request for comment to his client.
“We believe that Merck acted responsibly and in good faith in connection with the conduct at issue in these civil settlement agreements, including activities concerning the safety profile of Vioxx,” Merck general counsel Bruce Kuhlik said in a statement. The settlement also resolves claims lodged by 43 states and
the District of Columbia. The states of Alaska, Kentucky, Montana, Mississippi, Oklahoma, Pennsylvania, and Utah are continuing to press related claims, according to Merck.
Merck pulled Vioxx from the market in 2004, and in 2007 it agreed to settle civil suits over the drug's safety for $4.85 billion. In anticipation of the settlement, the company recorded a $950 million charge in October 2010.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
Defining commercial real estate asset class is essentially a property explaining how it identifies — not necessarily what its original intention was or what others think it ought to be. This article discusses, from a general issue-spot and contextual analysis perspective, how lawyers ought to think about specialized leasing formats and the regulatory backdrops that may inform what the documentation needs to contain for compliance purposes.
As courts and discovery experts debate whether hyperlinked content should be treated the same as traditional attachments, legal practitioners are grappling with the technical and legal complexities of collecting, analyzing and reviewing these documents in real-world cases.
How to Convey Your Merits In a Way That Earns Trust, Clients and Distinctions Just as no two individuals have the exact same face, no two lawyers practice in their respective fields or serve clients in the exact same way. Think of this as a "Unique Value Proposition." Internal consideration about what you uniquely bring to your clients, colleagues, firm and industry can provide untold benefits for your law practice.
The ever-evolving digital marketing landscape, coupled with the industry-wide adoption of programmatic advertising, poses a significant threat to the effectiveness and integrity of digital advertising campaigns. This article explores various risks to digital advertising from pixel stuffing and ad stacking to domain spoofing and bots. It will also explore what should be done to ensure ad fraud protection and improve effectiveness.
This article offers practical insights and best practices to navigate the path from roadmap to rainmaking, ensuring your business development efforts are not just sporadic bursts of activity, but an integrated part of your daily success.